PET/MRI and prostate cancer

被引：14
作者：
Piert M. [1 ]
El Naqa I. [2 ]
Davenport M.S. [1 ]
Incerti E. [3 ]
Mapelli P. [3 ]
Picchio M. [3 ]
机构：
[1] Department of Radiology, University of Michigan, Ann Arbor, MI
[2] Department of Radiation Oncology, University of Michigan, Ann Arbor, MI
[3] Department of Nuclear Medicine, IRCCS San Raffaele Scientific Institute, Milan
来源：
Clinical and Translational Imaging | 2016年 / 4卷 / 6期
关键词：
PET/MRI; Prostate cancer; [!sup]11[!/sup]C]choline; [!sup]18[!/sup]F]choline; [!sup]68[!/sup]Ga]PSMA;
D O I：
10.1007/s40336-016-0192-9
中图分类号：
学科分类号：
摘要：
Advances in medical imaging are needed to support the general goal of personalized patient-centric care. This is particularly true for prostate cancer, which frequently presents as the initial multifocal disease with variable significance and outcome, and, when aggressive, can recur after the initial definitive management. The combined simultaneous acquisition of multi-parametric magnetic resonance imaging and positron emission tomography (PET) can provide combined structural, metabolic, and functional imaging information regarding prostate cancer status in a whole-body single session examination. As described in this review article, combining PET and MRI appears particularly useful for pelvic disease assessments, as PET and MRI provide complementary information, which can be best obtained with hybrid PET/MR scanners. While there is growing interest in the field of prostate cancer imaging regarding the value of PET/MRI, the current literature in this field is sparse and insufficient for a systematic analysis. This article, therefore, highlights available evidence and future perspectives of PET/MRI for the initial diagnosis, staging, and restaging of prostate cancer with choline-based radiotracers as well as ligands to target prostate-specific membrane antigen. © 2016, Italian Association of Nuclear Medicine and Molecular Imaging.
引用
收藏
页码：473 / 485
页数：12
相关论文
共 72 条
[1]  
Cancer facts and figures, Atlanta, (2012)
[2]  
Robertson N.L., Emberton M., Moore C.M., MRI-targeted prostate biopsy: a review of technique and results, Nat Rev Urol, 10, pp. 589-597, (2013)
[3]  
Klotz L., Emberton M., Management of low risk prostate cancer: active surveillance and focal therapy, Curr Opin Urol, 24, pp. 270-279, (2014)
[4]  
Ross H.M., Kryvenko O.N., Cowan J.E., Simko J.P., Wheeler T.M., Epstein J.I., Do adenocarcinomas of the prostate with Gleason score (GS) ≤6 have the potential to metastasize to lymph nodes?, Am J Surg Pathol, 36, pp. 1346-1352, (2012)
[5]  
Klotz L., Emberton M., Management of low risk prostate cancer-active surveillance and focal therapy, Nat Rev Clin Oncol, 11, pp. 324-334, (2014)
[6]  
Rischke H.C., Eiberger A.K., Volegova-Neher N., Henne K., Krauss T., Grosu A.L., Et al., PET/CT and MRI directed extended salvage radiotherapy in recurrent prostate cancer with lymph node metastases, Adv Med Sci, 61, pp. 212-218, (2016)
[7]  
Heidenreich A., Bastian P.J., Bellmunt J., Bolla M., Joniau S., van der Kwast T., Et al., EAU guidelines on prostate cancer. part 1: screening, diagnosis, and local treatment with curative intent-update 2013, Eur Urol, 65, pp. 124-137, (2014)
[8]  
Evangelista L., Briganti A., Fanti S., Joniau S., Reske S., Schiavina R., Et al., New clinical indications for F/C-choline, new tracers for positron emission tomography and a promising hybrid device for prostate cancer staging: a systematic review of the literature, Eur Urol, (2016)
[9]  
Kitajima K., Murphy R.C., Nathan M.A., Froemming A.T., Hagen C.E., Takahashi N., Et al., Detection of recurrent prostate cancer after radical prostatectomy: comparison of 11C-choline PET/CT with pelvic multiparametric MR imaging with endorectal coil, J Nucl Med, 55, pp. 223-232, (2014)
[10]  
Fanti S., Minozzi S., Castellucci P., Balduzzi S., Herrmann K., Krause B.J., Et al., PET/CT with 11C-choline for evaluation of prostate cancer patients with biochemical recurrence: meta-analysis and critical review of available data, Eur J Nucl Med Mol Imaging, 43, pp. 55-69, (2016)
12345678